scholarly journals Correction: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Jacob J. Chabon ◽  
Andrew D. Simmons ◽  
Alexander F. Lovejoy ◽  
Mohammad S. Esfahani ◽  
Aaron M. Newman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Resistance Mechanisms ◽  
Dna Profiling ◽  
Egfr Inhibitor ◽  
Lung Cancer Patients ◽  
Inhibitor Resistance ◽  
Circulating Tumour Dna

scholarly journals Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Jacob J. Chabon ◽  
Andrew D. Simmons ◽  
Alexander F. Lovejoy ◽  
Mohammad S. Esfahani ◽  
Aaron M. Newman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Resistance Mechanism ◽  
Growth Factor Receptor ◽  
Resistance Mechanisms ◽  
Egfr Inhibitor ◽  
Tumour Heterogeneity ◽  
Lung Cancer Patients ◽  
Ctdna Analysis ◽  
Inhibitor Resistance ◽  
Circulating Tumour Dna

Abstract Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib. We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity. Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1. We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib. Increased MET copy number is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses. Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib. These results underscore the importance of tumour heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.

scholarly journals Case Report Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment

2014 ◽  
Vol 13 (4) ◽  
pp. 8657-8660 ◽  
Author(s):  
M.X. Zhang ◽  
W. Tan ◽  
R.X. Zhang ◽  
Y.L. Tian ◽  
H.M. Gao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Cancer Patients ◽  
Small Cell ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
Term Survival ◽  
Lung Cancer Patients ◽  
Inhibitor Treatment

scholarly journals Urinary circulating DNA profiling in non-small cell lung cancer patients following treatment shows prognostic potential

2018 ◽  
Vol 10 (7) ◽  
pp. 4137-4146 ◽  
Author(s):  
Tianjun Hu ◽  
Haibo Shen ◽  
Hongbo Huang ◽  
Meijun Song ◽  
Zhenghua Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Dna Profiling ◽  
Circulating Dna ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document